Two developments from earlier this year deserve more attention than they initially got, and both are clearer when you go back to the primary sources instead of relying on trade coverage.
Compass moves into PTSD
Compass Pathways is no longer just talking about PTSD as a future possibility. In January 2026, the company said FDA accepted its Investigational New Drug application for COMP360 in PTSD, clearing the way for a late-stage program. According to Compass, the planned study is COMP202, a phase 2b/3, multicenter, randomized, double-blind, controlled trial with an open-label extension.
The design is more concrete than the original short post captured. In the blinded portion, participants receive two administrations of COMP360 25 mg or two administrations of COMP360 1 mg, with the second session about four weeks later. The primary efficacy endpoint is change from baseline in CAPS-5 total severity score at Week 8. Compass says the follow-up phase then extends another 40 weeks, with eligible participants able to receive one open-label retreatment dose.
That matters because it shows Compass is trying to move PTSD into a more conventional late-stage development lane, not just waving at the indication. The company is also grounding the expansion in prior PTSD data. Its September 2025 release on the earlier phase 2 study says a single 25 mg COMP360 dose was tested in 22 patients with PTSD across three sites in the U.K. and U.S., was well tolerated with no serious adverse events, and showed rapid symptom improvement that remained visible out to 12 weeks. Compass also said those findings were published in the Journal of Psychopharmacology.
So the real update here is not simply that Compass wants to study PTSD. It is that the company is now presenting a specific late-stage trial design while pointing back to a small but formally published PTSD dataset as the bridge into that next phase.
Public support for psilocybin is rising, but it is still conditional
The RAND side of the story is also a little different when read directly. RAND's 2025 RAND Psychedelics Survey, published in February 2026, describes itself as the first probability-based and nationally representative survey to measure U.S. public opinion about legalizing psilocybin mushrooms, LSD, and MDMA separately rather than collapsing them into one psychedelic bucket.
The topline psilocybin number is a little lower, and more precise, than the original post suggested. RAND reports that 23 percent of U.S. adults support legal psilocybin mushrooms, not 25 percent. The survey was fielded from September 9 to October 1, 2025, and RAND says 10,122 panelists completed it with validated responses.
The more interesting finding is how qualified that support is. RAND says support for psilocybin is still far below cannabis, but also roughly where cannabis polling sat in the mid-1990s, just before state medical-cannabis laws began to spread. At the same time, support is clearly not a broad endorsement of anything-goes legalization. Among people who support legal psilocybin use, only 42 percent say adults should be able to use it for any reason. RAND also found that the most endorsed supply model was use at a medical facility under supervision at 49 percent, ahead of dispensary access at 28 percent and personal grow-or-forage access at 23 percent.
That is a more useful political read than a single headline percentage. Americans are becoming more open to psilocybin, but the openness is still tightly tied to treatment, supervision, and institutional guardrails rather than a simple recreational-legalization frame.